Novadaq Reports Second Quarter 2011 Financial Results
(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 08/04/11 -- Novadaq® Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced its financial results for the second quarter ended June 30, 2011. Unless otherwise indicated, all dollar amounts in this press release are expressed in United States (U.S.) dollars.
"We are seeing continued acceleration following the February 2011 commercial launch of SPY® Systems by our partners LifeCell™ and Intuitive Surgical®," said Dr. Arun Menawat, Novadaq President and CEO. "During the second quarter, Novadaq shipped 92 imaging systems compared to our original estimate of 70. All SPY Elite Systems are shipped directly to hospitals, while da Vinci® Fluorescence Imaging units are shipped to Intuitive for integration. Disposable kit shipments more than doubled between the first and second quarter 2011. Although the increased device and kit sales resulted in higher revenues and a lower quarterly operating loss, Novadaq did increase its use of cash due mainly to capital invested to grow the SPY Elite install base. We are pleased that a Canadian chartered bank has offered to Novadaq a revolving line of credit, which provides an additional source of capital to support this build-out if needed. The credit offer is subject to the bank's final due diligence and execution."
Dr. Menawat continued, "In April, the prestigious medical review journal, Clinics in Plastic Surgery, published an overview of fluorescence angiography authored by Duke University surgeon Dr. Michael Zenn. This publication certainly adds to the top tier support building around SPY, and advances the technology another step along the path to standard of care. SPY Imaging is gaining momentum in breast reconstruction surgery, and early feedback related to its use in robotic partial nephrectomy is positive. We look forward to continued growth in our current indications, as well as expanding into additional procedures where surgeons are telling us SPY adds value."
Conference Call
Novadaq is pleased to invite all interested parties to participate in a conference call on August 4th, at 5:00 p.m. Eastern Time during which the results will be discussed.
The call will be broadcast live over the Internet, hosted at the Company's website at under the "Events" tab in the "Investors" section and will be archived online for 365 days. In addition, a replay of the call will be available for download to a portable audio player or computer, as an MP3 or podcast file, at the same location on Novadaq's website.
To access the live conference call:
Live Participant Dial-In (Toll Free): (877) 407-8031
Live Participant Dial-In (International): (201) 689-8031
A telephonic replay of the conference call will be made available until midnight on September 4, 2011 and can be accessed by dialing 1-877-660-6853 (within Canada and the United States) or 1-201-612-7415 (international callers) and entering the account number 286 and the conference identification number 376214 when prompted. The call will be archived for 365 days on the company's website at under the "Events" tab in the Investors section. In addition, a replay of the call will be available for download to a portable audio player or computer, as an MP3 or podcast file, at the same location on Novadaq's website.
About Novadaq Technologies Inc:
Novadaq Technologies develops and markets real-time fluorescence imaging technologies for use in the operating room. The Company's core technology platform, SPY imaging, provides clinically relevant, anatomic and physiologic images during a wide variety of complex open and minimally invasive surgical ("MIS") procedures. SPY empowers surgeons treating life-threatening illnesses such as breast, colon and other cancers and cardiovascular disease to more effectively treat vascular blockages and assess tissue perfusion. More than 40 peer-reviewed publications demonstrate that SPY imaging leads to fewer post-operative complications and reduced hospital costs. The SPY imaging System is cleared by the United States Food and Drug Administration ("FDA") for real-time use during open and MIS surgical procedures. The endoscopic SPY System combines all of the capabilities of SPY imaging with state-of-the-art high definition ("HD") visible light visualization offered by conventional endoscopes. Novadaq announced its first alliance with Intuitive Surgical®, Inc., in January 2009, to integrate SPY Imaging into the 3-D HD imaging capabilities of the da Vinci® Surgical Robotic System. The integrated system received FDA 510(k) clearance to market in February 2011. In addition, in September 2010, Novadaq entered into an exclusive North American sales and marketing alliance with LifeCell™ Corporation, a Kinetic Concepts ("KCI"), Inc. Company, for SPY in open plastic and reconstructive, gastrointestinal and head and neck surgery. Novadaq's cardiac surgery products, including SPY imaging for cardiac applications and a Heart Laser™ System targeted at improving heart surgeries, are marketed through a direct sales team. For more information, please visit the Company's website at .
Forward Looking Statements:
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, results of future clinical tests of PINPOINT, SPY endoscopic technology and the SPY Imaging System, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Note: The SPY® Elite System is a trademark of LifeCell™ Corporation. LifeCell is a business unit of Kinetic Concepts, Inc. The da Vinci Surgical Robot is a registered trademark of Intuitive Surgical.
Contacts:
Investor Relations Contact: Novadaq Technologies Inc.
David C. Martin
Vice President, Business Development and Investor Relations
905-629-3822 ext: 218
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.08.2011 - 20:01 Uhr
Sprache: Deutsch
News-ID 42337
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Medical Devices
Diese Pressemitteilung wurde bisher 327 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novadaq Reports Second Quarter 2011 Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Novadaq Technologies Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
